A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects with higher risk myelodysplastic syndrome (Higher Risk-MDS).

计划入组 490 人 · 首次发布于 2024 年 10 月 15 日

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

计划入组 90 人 · 首次发布于 2024 年 1 月 9 日

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

计划入组 54 人 · 首次发布于 2024 年 6 月 24 日

X1 (Emergent BioSolutions)

Autologous chondrocyte implantation (Biosolutions)

ZIKV IG(Emergent BioSolutions)

Emergent BioSolutions

United States

Immune Biosolutions Inc

Canada

Emergent Biosolutions Inc.

United States

AI and Automation Set to Transform Pharmaceutical R&D: Industry Faces Cultural and Technical Hurdles

Brincidofovir Evaluated in Africa CDC-Led Trial for Mpox Treatment

Emergent BioSolutions Secures FDA Approval for Raxibacumab Manufacturing at Winnipeg Facility